Check-Cap is a clinical-stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan, a patient-friendly, preparation-free screening test that enables early intervention and cancer prevention by detecting polyps before they may develop into colorectal cancer.The company’s capsule-based screening technology is designed to significantly increase screening adherence worldwide, helping millions of people to stay healthy through preventive CRC screening.

C-Scan uses an ultra-low dose X-ray capsule; an integrated positioning, control, and recording system; and proprietary software to generate a 3D map of the inner lining of the colon as the capsule travels naturally along the gastrointestinal tract.

C-Scan is noninvasive and requires no sedation or bowel preparation, allowing patients to continue their daily routine without interruption.

C-Scan is not intended to replace colonoscopies, and a positive C-Scan result should be followed by colonoscopy.In March 2021, the FDA approved Check-Cap’s investigational device exemption application, permitting it to begin a pivotal study of C-Scan in the United States.